Posted by AGORACOM-JC
at 10:28 AM on Friday, September 11th, 2020
SPONSOR: FansUnite Entertainment Inc (CSE: FANS) The global online gambling market could potentially hit $1 TRILLION by the end of this decade. FansUnite is well positioned to capitalize on this trend. The company has a full suite of B2B and B2C services and has facilitated over $350M in bets from its 300,000 registered users. Learn More.
Twitch brings custom esports competitions to streamers in closed beta
Versus is a suite of tools that allows players, organizers, and streamers to host competitions with their communities
Twitch and esports go together like a dusting of salt on top of a chocolate chip cookie: the sweetness of victory etc., tempered by the saltiness of defeat
Today, Twitch launches Versus — a suite of competitive tools that will let creators on the site organize and manage their own tournaments — which promises to bring those agonies and ecstasies to any streamer who feels like pubstomping their community
Twitch and esports go together like a dusting of salt on top of a chocolate chip cookie: the sweetness of victory etc., tempered by the saltiness of defeat. Today, Twitch launches Versus — a suite of competitive tools that will let creators on the site organize and manage their own tournaments — which promises to bring those agonies and ecstasies to any streamer who feels like pubstomping their community.
While the feature is in closed beta for now, collegiate esports leagues, game devs, and Twitch Rivals competitors (along with some other Twitch streamers) will have access starting today. There is a waitlist you can join if you’re interested in trying out Versus for yourself.
Obviously, this isn’t Twitch’s first foray into esports. Twitch Rivals has been hosting competitions between streamers and pros since last year, and in April, the company rolled out an esports directory to keep viewers updated on the latest tournaments. What’s interesting about Versus is how it’s very similar to Facebook Gaming’s Tournaments. Twitch is playing catch-up! Even so, it’s cool to see good ideas make their way further into the mainstream.
Posted by AGORACOM-JC
at 3:55 PM on Thursday, September 10th, 2020
SPONSOR: Else Nutrition Holdings Inc. (TSX-V: BABY) The award winning, plant-based nutrition company for small cap investors. The company has a $7,000,000 cash balance for US product launch with International agreements coming soon. Learn More.
Plant-based diets shine when looking at the gut health
Microbiome of the gut is created at birth, the study notes, but continues to develop throughout infancy and is significantly affected throughout childhood by diet
There is a large shift in the composition of the gut as infants are weaned and begin consuming solid foods, with the makeup of the gut resembling that of adults by about age 3 years
A recent study investigating how foods impact gut health in children points to plant-based proteins, fresh fruits and vegetables, and grains as key to a diverse and healthy microbiome.
There has been a wealth of evidence collected on how important the gut microbiome is for health maintenance, but little research has been done on how diet habits are related to gut health in prepubescent children. A recent study took a closer look.
The study,1 published in the Journal of the Academy of Nutrition and Dietetics, reveals that gut health in young children and pre-pubescent teenagers is both dynamic and diverse, and is particularly responsive to certain food groups.
“The gut microbiome remains dynamic for children past 3 years of age and responds to dietary differences,” says lead author Dena Herman, PhD, MPH, RD, professor at California State University, Northridge and director of the MCH Nutrition Leadership Training Program at the UCLA Fielding School of Public Health. “This represents an opportunity to learn healthy habits early in life so that they can be sustained over the life course to maximize health.”
The health of the gut plays a vital role in maintaining health and supporting immune functions, the study notes. The microbiome is impacted by a number of factors, with individualized diets being one of the most important determinants of a diverse gut environment.
The microbiome of the gut is created at birth, the study notes, but continues to develop throughout infancy and is significantly affected throughout childhood by diet. There is a large shift in the composition of the gut as infants are weaned and begin consuming solid foods, with the makeup of the gut resembling that of adults by about age 3 years. Little research has been done on the makeup of the childhood gut between 3 years of age and the adolescent years, the study notes, but dietary patterns have been associated with significant differences in the guts of children in the age range of 4 to 8 years. As diets have shifted more toward a Western diet, heavily featuring highly processed foods and high-fat animal products, more and more diseases have been attributed to an imbalance in the microbial composition of the gut, the study reveals.
To examine how diet influenced gut health in the study group, researchers asked parents to collect fecal samples and quantitative 24-hour diet recalls, investigating each 3 times, each time about 6 days apart. The team examined how diet impacted gut health by splitting children into groups based on the types of food they consumed. Protein consumption—both animal- and plant-based—was the only food group that was associated with gut diversity. Total grain and vegetable consumption, on the other hand, heavily influenced the community makeup of the microbiome, the study notes. The research team noted some surprise here, in that yogurt was the only animal-derived food that was associated with the membership and structure of the microbiome. Instead, proteins were more closely linked to higher levels of diversity in the types of microorganisms found in the gut, the study states. The most abundant microorganisms found in the study groups were Bacteroides and Prevotella. The first was tied to Western diets, and the latter to fiber-rich diets.
Adequate diversity in the microbiome samples was noted, with results appropriate for the cohort’s age group. The research team found that older children in the study group had more diversity in their gut microbiomes, and that gender had no impact on the results. There were a number of trends noted with different food groups, such as lower diversity with a high non- whole-food grain consumption, and abundance of certain bacteria groups with higher consumption of fruit and fiber.
Overall, the study revealed that fresh fruits and vegetable consumption led to increased variation in the structure of the microbiome—with citrus, melon, and berries contributing most to gut diversity. Whole and non-whole grains were key to maintaining gut health, immune health, and glucose regulation, Herman stated. B-vitamins also played a big role in gut health, contributing to microbiome structure and composition, she says.
The 2- to 9-year-old group studied in this report is significant, because this represents a time when diets are becoming more diverse, and children begin to explore and become more independent in their eating habits. The study highlights the need to make this time count, the study notes, with guidance from adults on healthy eating habits to help promote good health and disease prevention in adulthood.
“Early and middle childhood may represent a crucial window when the gut microbiome might still be amenable to lasting manipulations through diet,” the study reveals.
The study emphasizes the importance of diet in the development of a healthy microbiome during the childhood years, with non-whole-grain foods enriched with vitamins and minerals being perhaps one of the largest contributors to gut health in this pilot sample.
“There are many benefits of a healthy gut for children. First and foremost, is an enhanced immune response. Young children are often more susceptible to upper respiratory tract infections and ear infections, especially if they are in childcare and as they enter school,” Herman explains. “By maintaining a diverse diet, children have a better chance of maximizing the healthy bacteria that can support immune health.”
The benefits of a healthy gut don’t end with physical health, she adds. Mental health effects were not the focus of the study, Herman says, but there has been prior research drawing a strong connection between gut health and brain health.
“For children this could translate into better focus in school allowing them to reach their academic potential. Unlike other studies, this study showed that children past 3 years of age are still able to change the structure and membership of their microbiome through the foods that they eat,” she says. “This is exciting and helps us extend the findings from studies in adults to children. The benefits described for children are similar for adults. However, as we age we have increased risk for inflammation, which can lead to higher rates of chronic diseases including cancers. That is why it is important to start healthy habits as early in life as possible.”
Although the study was small, it was more detailed than most previously conducted research examining gut health in children, she says. It highlights the benefits of plant-based diets, which Herman says she hopes will convince parents and clinicians to make changes—both for their children and themselves.
“I would hope that the results we have shared provide further support for the promotion of a plant-based diet—not only for young children, but also for adults. Parents are role models for their children’s eating habits and this study shows that we can actively engage in making positive changes to our gut health and overall health starting at a young age,” Herman says. “As a pediatric dietitian myself, I would hope that we could work together with the medical community, particularly pediatricians, to promote healthy habits including healthful eating habits and regular exercise through anticipatory guidance at all well-child visits. With the high rates of obesity in the United States, having children consume foods that support reduced risk for obesity may translate into lower risks for obesity-related diseases in adulthood such as cardiovascular disease and diabetes. Starting this practice as early as possible will ensure the most benefit for these children and generations to come.”
Reference
1. Herman D, Rhoades N, Mercado J, Argueta P, Lopez U, Flores G. Dietary habits of 2- to 9-year-old american children are associated with gut microbiome composition. J Acad Nutr Diet. 2020;120(4):517-534. doi:10.1016/j.jand.2019.07.024
Posted by AGORACOM-JC
at 3:29 PM on Thursday, September 10th, 2020
Kontrol BioCloud a Safe Space Technology™
Received positive lab results for BioCloud testing against the live virus that causes COVID-19
This positive result follows two successful tests against the dormant SARS-CoV-2 virus
“This technology can improve our surveillance of SARS-CoV-2 by monitoring air quality in multiple settings.”
Dr. Jimmy D. Dikeakos, Ph.D
“This technology will allow for measurement of many different viruses, bacteria, and fungi beyond the immediate need for the virus that causes COVID-19.”
Dr. David Heinrichs, Ph.D
TORONTO, ON / September 10, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to provide an update on its Kontrol BioCloud (or “BioCloud“) technology.
Lab Testing with Live Virus
Kontrol has received positive lab results for BioCloud testing against the live virus that causes COVID-19. This positive result follows two successful tests against the dormant SARS-CoV-2 virus (see press release dated August 10th, 2020 and press release dated August 27th, 2020).
“We are very pleased that through a methodical approach we have been able to successfully test our technology with the live virus causing COVID-19 and will turn our focus to commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “It has been a long journey to get to this point since the initial concept design in March 2020 and through the great efforts of our team we look forward to delivering a safe space technology solution.”
“This technology can improve our surveillance of SARS-CoV-2 by monitoring air quality in multiple settings.”
Dr. Jimmy D. Dikeakos, Ph.D
“This technology will allow for measurement of many different viruses, bacteria, and fungi beyond the immediate need for the virus that causes COVID-19.”
Dr. David Heinrichs, Ph.D
Commercialization
Kontrol will begin the commercialization process of BioCloud by initiating an application to the CSA Group. CSA is a leader in Standards Development and in Testing, Inspection and Certification around the world including Canada, the U.S., Europe and Asia. The CSA registered mark shows that a product has been independently tested and certified to meet recognized standards for safety or performance. Kontrol anticipates that a CSA approval can take from 30 to 45 days to complete and Kontrol has a history of working with CSA on various air quality and emission products. During the process of CSA approval, Kontrol will seek to establish lower detection limits of the COVID-19 virus. Lower detection limit specifications are part of the commercial specifications that Kontrol will deliver for a fully commercialized product.
“We are very pleased to start the process of sharing our technology with the market through the commencement of commercialization,” says Gary Saunders, VP of Kontrol. “We want to thank our lab partners for all of their expertise and dedication. The lab procedures involved significant planning and preparation to execute meticulous testing against the live COVID-19 virus. We look forward to sharing our results with all levels of Government in the coming days and weeks ahead.”
Manufacturing Capacity
Kontrol has commenced discussions with two global outsource contract manufacturers who can provide Kontrol with external manufacturing capacity. Kontrol is not making any statements or assumptions about potential revenues, however, Kontrol is planning for up to 20,000 BioCloud units per month as manufacturing capacity. This is part of Kontrol’s prudent overall planning and access to manufacturing capability.
About Kontrol BioCloud
BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, retirement homes, hospitals, mass transportation and others. It can be an important technology which supports the entire system of individual testing and contact tracing.
The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).
About Kontrol Energy
Kontrol Energy Corp. (CSE: KNR) (OTCQB: KNRLF) (FSE: 1K8) is a leader in the energy efficiency sector through IoT, Cloud and SaaS technology. With a disciplined mergers and acquisition strategy, combined with organic growth, Kontrol Energy Corp. provides market-based energy solutions to our customers designed to reduce their overall cost of energy while providing a corresponding reduction in greenhouse gas (GHG) emissions.
Kontrol Energy is one of Canada’s fastest growing companies in 2018 and 2019 as ranked by Canadian Business and Maclean’s.
Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com.
For further information, contact:
Paul Ghezzi, Chief Executive Officer [email protected] or [email protected] Kontrol Energy Corp., 180 Jardin Drive, Unit 9, Vaughan, ON L4K 1X8 Tel: 905.766.0400, Toll free: 1.844.566.8123
Neither IIROC nor any stock exchange or other securities regulatory authority accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy.
Where the Company expresses or implies an expectation or belief as to future events or results, such expectation or belief is based on assumptions made in good faith and believed to have a reasonable basis. Such assumptions include, without limitation, that sufficient capital will be available to the Company and that technology will be as effective as anticipated.
However, forward-looking statements are subject to risks, uncertainties, and other factors, which could cause actual results to differ materially from future results expressed, projected, or implied by such forward-looking statements. Such risks include, but are not limited to, that sufficient capital and financing cannot be obtained on reasonable terms, or at all, that technologies will not prove as effective as expected, that customers and potential customers will not be as accepting of the Company’s product and service offering as expected, and government and regulatory factors impacting the energy conservation industry. In particular, successful development and commercialization of the Kontrol BioCloud Analyzer are subject to the risk that the Kontrol BioCloud Analyzer may not prove to be successful in detecting the virus that causes COVID-19 effectively or at all, uncertainty of timing or availability of any regulatory approvals and Kontrol’s lack of track record in developing products for medical applications.
Accordingly, undue reliance should not be placed on forward-looking statements and the forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. The forward-looking statements contained herein are made as at the date hereof and are based on the beliefs, estimates, expectations, and opinions of management on such date. Kontrol does not undertake any obligation to update publicly or revise any such forward-looking statements or any forward-looking statements contained in any other documents whether as a result of new information, future events or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required under applicable securities law. Readers are cautioned to consider these and other factors, uncertainties, and potential events carefully and not to put undue reliance on forward-looking information.
Investing in precious metals you would be forgiven for putting a very heavy focus on the popular names in the sector. Trading in gold and silver obviously attracts much more attention in this area, mainly due to the general level of awareness that most people have around these very common market choices. There are other precious metals that are definitely worth investing in though. One of these which is often forgotten about by retail traders, is palladium. Despite the fact this precious metal has grown strongly in recent years, and has displayed gains of more than 1,000% since 2008, it is often left aside by investors focused on the higher volume gold and silver markets.
Here we will show you what the palladium market is all about, how you can get into trading this precious metal, and why it may be a great addition to your portfolio.
The Basics – What Drives Palladium Prices?
At the present time, palladium is trading higher than gold, with both at record high points. This has shone a light on both like never before. So, what are the main factors which have driven the prices of palladium to put them at higher levels even than gold? Here are a few major ones to consider:
Auto Industry Demand – This is by far the number one influence on the prices of palladium around the world. The auto industry accounts for around three quarters of the global demand for palladium. This is due to the fact that palladium is a key component in the manufacturing of catalytic converters. This, and particularly the demand for vehicles in large markets like the US and China have a huge bearing on the price of palladium.
Geopolitical Concerns – This factor can be active on a number of fronts for palladium and is something you should investigate prior to investing. Much of the world’s palladium supply comes from Russia, and South Africa. This accounts for about 80% of the total supply worldwide. With that said, any interruptions to this supply or process, be it in the form of sanctions as Russia sometimes deals with, or power supply problems, can cause a fluctuation in prices.
Substitution – Substituting palladium for other metals within the auto industry is something which is coming under and increasing amount of scrutiny. This is in large due to the high price of palladium, and also the fact that a number of substitutes, including platinum can be used. With that in mind though, platinum is not a direct substitute that can be easily used, so car makers are still largely reliant on palladium.
US Dollar Strength – The US Dollar forex market is going through a tough time currently. This weakening dollar can certainly have an impact on palladium prices as it does on other precious metals, though the reasoning behind it may be different. Palladium is typically purchased from suppliers in US Dollars. Any downward movement in the Dollar has potential to act as a disincentive top suppliers. This can reduce the supply of the precious metal which in turn can lead to an upward price movement.
Ways to Invest in Palladium
Now that you know several of the key drivers behind the price of palladium, it puts you in a good position to get involved in buying and trading the market. There are several ways in which you can do this much trading gold or silver markets. The main points which will vary here are the liquidity, and how closely the investment is tied to the palladium price.
The most direct way to get involved in trading palladium is to purchase palladium bullion directly from a reputed mint or other trustworthy supply source. This physical purchase of the metal typically takes the form of coins, collectable coins, or bars of the metal which can be purchased at different weights. Naturally, this is absolutely tied to the palladium market prices, though you should be mindful that a small premium is generally added by the seller, and this can be a substantially more difficult palladium investment to resell quickly if the price changes.
Palladium stocks are another popular way to get involved in trading the market. This means buying stocks in palladium related companies through your broker. They are typically very closely connected to the demand and price for palladium, though you also have to be careful to understand the key metrics of the individual company performance too. If you are looking for an even higher volume market, you may choose to trade palladium options or futures contracts. These can be higher risk, but are certainly the most liquid in terms of your ability to quickly trade palladium.
Finally, if you are seeking a very well-balanced way to invest in palladium, ETFs may be a good choice for you. There are essentially baskets of stocks which you can invest in at one collective price. Investing in a thematic ETF related to palladium will give you good exposure to many of the main players in the sector, and should also hedge your risk to a certain extent if the prices do fall. These ETFs can often pay a healthy dividend too.
Who Should Invest in Palladium?
Although palladium is now at a higher price point than gold, it is still very much an investment that any type of trader can make. Like other precious metal investments, it is something you can use to add great diversity to your portfolio. It is also becoming very accessible to all retail traders thanks to being on offer from many of the top online brokers.
Your investment in palladium really depends on your risk profile. This will determine which method of palladium investment may be most suitable for you. If you are willing to take more risk and can withstand a degree of volatility, you may consider options, or futures, while a more conservative approach would be an investment in ETFs or certain index funds. With the growth in demand and price though, it is clear that more and more traders are becoming aware of the potential within trading palladium as much as other precious metals.
Posted by AGORACOM-JC
at 8:14 AM on Thursday, September 10th, 2020
Announced that it has entered into a sales agreement with 7-Eleven Korea for Robotic Process Automation infrastructure.
RPA is the technology that enables anyone to configure computer software today, or a “robot” to replicate and incorporate the actions of a person working within digital systems to conduct a business process
Global RPA market size is expected to reach $7.2 billion by 2025, rising at a market growth of 32.6% CAGR during the forecast period
Toronto, Ontario–(September 10, 2020) – Datametrex AI Limited (TSXV: DM) (FSE: D4G) (OTC Pink: DTMXF) (the “Company” or “Datametrex“) is pleased to announce that it has entered into a sales agreement with 7-Eleven Korea for Robotic Process Automation (“RPA”) infrastructure.
The global RPA market size is expected to reach $7.2 billion by 2025, rising at a market growth of 32.6% CAGR during the forecast period. RPA is the technology that enables anyone to configure computer software today, or a “robot” to replicate and incorporate the actions of a person working within digital systems to conduct a business process. An increased demand for business process automation (“BPA”) is expected to be the main growth driver through the use of Artificial Intelligence (“AI”) and RPA.[1]
7-Eleven is a international chain of convenience stores founded in 1927 in the United States with over 70,000 stores located around the globe. 7-Eleven has a legacy of innovation and delivering “what the customers want, when and where they want it.”
Datametrex is working closely with clients to power it through their digital initiatives and improve their delivery on innovation as they continue the pursuit of catering to a modern, digital-savvy generation of shoppers.
“At Datametrex, we continue our efforts to facilitate ground-breaking technologies to companies across the globe. Our technology is proven to be valuable to make sense of the data beyond complicated spreadsheets.” said Marshall Gunter, CEO of Datametrex. “We pride ourselves in providing tools that our clients can use to visualize their customer and stakeholder data. Through predictive analysis they can support their decision making, mitigate risk, and improve their bottom line.”
Investor Webinar
Datametrex also announces that senior management will be hosting an investor update webinar on Tuesday, September 15, 2020, at 1:00 p.m. ET to discuss the Company’s Second Quarter 2020 results, developments and contracts on the Artificial Intelligence technologies and COVID-19 test kits.
Datametrex plans to answer questions previously sent to [email protected]and during the webinar, at management’s discretion and subject to time constraints.
About Datametrex
Datametrex AI Limited is a technology focused company with exposure to Artificial Intelligence and Machine Learning through its wholly owned subsidiary, Nexalogy (www.nexalogy.com). Datametrex’s mission is to provide tools that support companies in fulfilling their operational goals, including Health and Safety, with predictive and preventive technologies. By working with companies to set a new standard of protocols through Artificial Intelligence and health diagnostics, the Company provides progressive solutions to support the supply chain. Additional information on Datametrex is available at www.datametrex.com.
For further information, please contact:
Marshall Gunter – CEO Phone: (514) 295-2300 Email: [email protected]
Neither the TSX Venture Exchange nor it’s Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Forward-Looking Statements
This news release contains “forward-looking information” within the meaning of applicable securities laws. All statements contained herein that are not clearly historical in nature may constitute forward-looking information. In some cases, forward-looking information can be identified by words or phrases such as “may”, “will”, “expect”, “likely”, “should”, “would”, “plan”, “anticipate”, “intend”, “potential”, “proposed”, “estimate”, “believe” or the negative of these terms, or other similar words, expressions and grammatical variations thereof, or statements that certain events or conditions “may” or “will” happen, or by discussions of strategy. Readers are cautioned to consider these and other factors, uncertainties and potential events carefully and not to put undue reliance on forward-looking information. The forward-looking information contained herein is made as of the date of this press release and is based on the beliefs, estimates, expectations and opinions of management on the date such forward-looking information is made. The Company undertakes no obligation to update or revise any forward-looking information, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.____________________________________
Posted by AGORACOM-JC
at 6:56 AM on Thursday, September 10th, 2020
Commenced COVID-19 reverse transcription polymerase chain reaction (RT-PCR), testing through its Sun Valley Health operations in Arizona, using RT-PCR test kits and laboratory test processing by Kai Medical Laboratory in Dallas, TX., the recently announced proposed acquisition target by Empower
programs are part of a “Back to Work” and “Back to School” initiative supported by a variety of outbound marketing campaigns including new Facebook ads, text message & email campaigns and outbound call-center campaigns targeting businesses, universities & colleges, sports teams or organizations where effective social distancing could be difficult.
VANCOUVER BC / September 10, 2020 / EMPOWER CLINICS INC.(CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) today announces it has commenced COVID-19 reverse transcription polymerase chain reaction (RT-PCR), testing through its Sun Valley Health operations in Arizona, using RT-PCR test kits and laboratory test processing by Kai Medical Laboratory in Dallas, TX., the recently announced proposed acquisition target by Empower.
The programs are part of a “Back to Work” and “Back to School” initiative supported by a variety of outbound marketing campaigns including new Facebook ads, text message & email campaigns and outbound call-center campaigns targeting businesses, universities & colleges, sports teams or organizations where effective social distancing could be difficult.
Currently Kai Medical Laboratory has the capacity to complete in excess of 2,000 RT-PCR tests in one eight-hour shift by utilizing its Thermo Fisher QuantStudio 12k Flex testing machine.
“Launching our RT-PCR testing programs utilizing the capability of Kai Medical Labs gives us the ability to access massive testing volume not only in Arizona, but nationwide in the U.S.” said Steven McAuley, Empower’s Chairman & CEO. “Our team at Sun Valley Health has created numerous strategic marketing campaigns to drive awareness and testing volume, leveraging our supply chain improvements with increased profit margins.”
Many schools and universities are now requiring students and teachers to provide RT-PCR testing results prior to returning to campus. Our nasal or throat swab RT-PCR testing program allow students and teachers to quickly be tested and receive results from a Clinical Laboratory Improvement Amendments (CLIA), accredited laboratory in only 24 – 48 hours.
Businesses need a stable workforce, and must be quick to isolate employees with any symptoms. Our RT-PCR testing allows employees to be tested quickly and receive results within 24 – 48 hours, giving the employee and the employer the opportunity to activate non-contagious employees and safely return to work!
Travelers are also discovering demands to get a RT-PCR test and provide the result upon check-in at the airport. The reports are required to be no more than 3 days old. Our testing program provides accurate results within 24-48 hours, giving the patient a document that can make the difference in being able to travel.
An RT-PCR assay is a viral molecular test to detect active infection directly in a patient’s RNA genetic sequence. An RT-PCR swab test is considered the gold-standard for testing & diagnosing active viral infections and should be used for anyone who has symptoms or known exposure to COVID-19. These tests are renowned for high sensitivity and high specificity.
(CLIA) The Clinical Laboratory Improvement Amendments regulate laboratory testing and require clinical laboratories to be certified by the Center for Medicare and Medicaid Services (CMS) before they can accept human samples for diagnostic testing.
USA COVID-19 Data as at September 9, 2020 TOTAL CASES: 6,310,663 TOTAL DEATHS: 189,147 CASES IN LAST 7 DAYS: 262,971
ARIZONA as at September 9, 2020 CONFIRMED CASES: 204,239 PROBABLE CASES: 1,806 TOTAL CASES: 206,045 CASES IN LAST 7 DAYS: 3,703 CASES/100K: 2,873 DEATHS/100K: 72
TEXAS as at September 9, 2020 TOTAL CASES: 641,791 CASES IN LAST 7 DAYS: 24,458 CASES/100K: 2,236 DEATHS/100K: 47
ABOUT EMPOWER
Empower is a vertically integrated health & wellness company with a network of corporate and franchised health & wellness clinics in the U.S. The Company is focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has launched Dosed Wellness Ltd. to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative.
ABOUT Kai Medical Laboratory
Kai Medical Laboratory is a high-complexity CLIA and COLA accredited Laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. Kai Medical Laboratory offers a wide array of testing services ranging from hematology to hormone testing, endocrinology, toxicology, and immunology. These tests are done under the supervision of its well-qualified and highly experienced scientists, medical professionals, and pharmacists. https://www.kaimedicallaboratory.com
This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the proposed acquisition of Sun Valley; the proposed transaction terms; the expected number of clinics and patients following the closing; the future potential success of Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.
Posted by AGORACOM-JC
at 2:46 PM on Wednesday, September 9th, 2020
On target to produce strongly sought-after nano silicon powders and nanowires for delivery and testing to battery industry parties in December
Company also confirms the September 3, 2020 closing of the $2,700,000 at $0.60, non-brokered private placement, announced on September 1, 2020
Now well funded to push forward on our nano silicon initiatives for the battery sector and others renewable energy applications, from which HPQ has currently announced two (2) NDA’s (Non-Disclosure Agreements)
MONTREAL, Sept. 09, 2020 — HPQ Silicon Resources Inc. (“HPQ” or “the Company”) TSX-V: HPQ; FWB: UGE; Other OTC : URAGF; is issuing this press release in response to recent market activity. HPQ does not usually comment on stock price and trading activity, however, given recent activity and inquiries from investors, the Company would like to confirm that everything material about the Company’s operations has been disclosed and that HPQ is on target to produce our strongly sought-after nano silicon powders and nanowires for delivery and testing to battery industry parties in December.
The Company also confirms the September 3, 2020 closing of the $2,700,000 at $0.60, non-brokered private placement, announced on September 1, 2020. As a result of this financing, HPQ has never been as well funded to push forward on our nano silicon initiatives for the battery sector and others renewable energy applications, from which HPQ has currently announced two (2) NDA’s (Non-Disclosure Agreements).
“HPQ PUREVAPTM Quartz Reduction Reactor (QRR) and HPQ NANO PUREVAPTM Nano Silicon Reactor (NSiR) processes are unique processes that will allow us to deliver to advanced materials companies and battery manufacturers a cost competitive, tailor-made product, that can replace graphite in batteries and thereby allow the deployment of truly powerful next generation Li-ion batteries,” said Bernard Tourillon, President & CEO of HPQ Silicon. “These processes open up unique multibillion-dollar business opportunity for HPQ and PyroGenesis, as we strive to deliver the critical Silicon nano-materials required by the surging Li-ion battery market and other large renewable energy markets.”
INTEREST IN PUREVAPTM NSiR GAME CHANGING LOW COST POTENTIAL
Research indicates that replacing graphite with Nano Silicon (Si) Powders could allow the manufacturing of high-performance Li-ion batteries to deliver an almost tenfold (10x) increase in anode capacity, inducing a 20-40% gain in the energy density of the next generation of Li-Ion batteries. Silicon Nanomaterial potential to meet energy storage demand of the future is undeniable and is generating massive investments.
Despite the strong research and investment in Silicon nanomaterial, current manufacturing processes to make Nano Silicon powders are not scalable or commercially viable. By December of this year, HPQ will be on the starting blocks of demonstrating a process that can address both the scalability and cost hurdles required by the industry.
About Silicon
Silicon (Si), also known as silicon metal, is one of today’s strategic materials needed to fulfil the Renewable Energy Revolution (“RER”) presently under way. Silicon does not exist in its pure state; it must be extracted from quartz (SiO2), in what has historically been a capital and energy intensive process.
About HPQ Silicon
HPQ Silicon Resources Inc. (TSX-V: HPQ) is a Canadian producer of Innovative Silicon Solutions, based in Montreal, building a portfolio of unique high value specialty silicon products needed for the coming RER.
Working with PyroGenesis Canada Inc.(TSX-V: PYR), a high-tech company that designs, develops, manufactures and commercializes plasma – based processes, HPQ is developing:
The PUREVAPTM “Quartz Reduction Reactors” (QRR), an innovative process (patent pending), which will permit the one step transformation of quartz (SiO2) into high purity silicon (Si) at reduced costs, energy input, and carbon footprint that will propagate its considerable renewable energy potential; º HPQ believes it will become the lowest cost (Capex and Opex) producer of silicon (Si) and high purity silicon metal (3N – 4N Si);
The PUREVAPTM Nano Silicon Reactor (NSiR), a new proprietary process that can use different purities of silicon (Si) as feedstock, to make spherical silicon nanopowders and nanowires; º HPQ believes it can also become the lowest cost manufacturer of spherical Si nanopowders and silicon-based composites needed by manufacturers of next-generation lithium-ion batteries; º During the coming months, spherical Si nanopowders and nanowires silicon-based composite samples requested by industry participants and research institutions’ will be produced using PUREVAPTMSiNR.
HPQ is also working with industry leader Apollon Solar of France to:
Use their patented process and develop a capability to produce commercially porous silicon (Si) wafers and porous silicon (Si) powders; º The collaboration will allow HPQ to become the lowest cost producer of porous silicon wafers for all-solid -state batteries and porous silicon powders for Li-ion batteries. º The plan is to deliver porous Si wafer to a battery manufacturer (under NDA) for testing in 2020.
This News Release is available on the company’s CEO Verified Discussion Forum, a moderated social media platform that enables civilized discussion and Q&A between Management and Shareholders.
Disclaimers:
The Corporation’s interest in developing the PUREVAP™ QRR and any projected capital or operating cost savings associated with its development should not be construed as being related to the establishing the economic viability or technical feasibility of any of the Company’s Quartz Projects.
This press release contains certain forward-looking statements, including, without limitation, statements containing the words “may”, “plan”, “will”, “estimate”, “continue”, “anticipate”, “intend”, “expect”, “in the process” and other similar expressions which constitute “forward-looking information” within the meaning of applicable securities laws. Forward-looking statements reflect the Company’s current expectation and assumptions and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated. These forward-looking statements involve risks and uncertainties including, but not limited to, our expectations regarding the acceptance of our products by the market, our strategy to develop new products and enhance the capabilities of existing products, our strategy with respect to research and development, the impact of competitive products and pricing, new product development, and uncertainties related to the regulatory approval process. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties and other risks detailed from time-to-time in the Company’s on-going filings with the security’s regulatory authorities, which filings can be found at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information contact
Bernard J. Tourillon, Chairman, President and CEO Tel (514) 907-1011 Patrick Levasseur, Vice-President and COO Tel: (514) 262-9239 http://www.hpqsilicon.com Email: [email protected]
Posted by AGORACOM-JC
at 1:18 PM on Wednesday, September 9th, 2020
You’re invited to our Investor Webinar on September 15th @ 1 PM EST. We will be discussing the Q2 financials, and the following topics: COVID-19 Testing and AI technology.
Posted by AGORACOM-JC
at 8:20 AM on Wednesday, September 9th, 2020
Completed management changes to enhance its focus on its dermatological services and products including DermSecure™ and SIAscopy™
Mike Druhan, who has championed SIAscopy™ within the Company for a number of years, has been appointed President, Dermatological Services and Products.
MedX Health Corp. (“MedX” or the “Company”) (TSX-V: MDX) announced that it has completed management changes to enhance its focus on its dermatological services and products (“DSP”) including DermSecure™ and SIAscopy™.
Mike Druhan, who has championed SIAscopy™ within the Company for a number of years, has been appointed President, Dermatological Services and Products. The supporting teams in sales, training, production as well as software and hardware development for DSP will report to Mr. Druhan. “Mike and his team will continue to build out the Brazilian, Canadian and Dutch markets where we have established sales but more importantly, this refocus will allow more resources to be devoted to our initiatives in the United States, Latin America and Europe,” said Rob von der Porten, Executive Chair and interim CEO.
“I have full confidence in the capability of my team and the outstanding strengths of our technologies, SIAscopy™ and DermSecure™, which together form, in our view, the leading teledermatological offering in the world,” noted Mike Druhan. “As we have already seen, it saves lives and has a huge potential that we are starting to exploit. Consequently, we are relaunching the MedX website in the coming week, with much improved content on our dermatological focus, in keeping with our driving strategy,” he continued.
Louie Canitano, who has many years of experience in therapeutic laser and light products has been appointed Managing Director Light Therapy Products, with responsibility over sales of these products in Canada and the United States. He will work with our Canadian and US-based sales and distributor network.
About MedX
MedX, headquartered in Mississauga, Ontario, is a leading medical device and software company focused on skin health with its SIAscopy™ on DermSecure™ telemedicine platform, utilizing its SIAscopy™ technology. SIAscopy is also imbedded in its products SIAMETRICS™, SIMSYS™, and MoleMate™, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS™, SIMSYS™, and MoleMate™ include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are Health Canada, FDA, TGA and CE cleared for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey. MedX also designs, manufactures and distributes quality light therapy products, including therapeutic and dental lasers to provide drug-free and non-invasive treatment of tissue damage and pain. www.medxhealth.com.
This press release does not constitute an offer of any securities for sale. This press release contains certain forward-looking statements within the meaning of applicable Canadian securities legislation. These forward-looking statements involve certain risks and uncertainties that could cause actual results to differ, including, without limitation, the company’s limited operating history and history of losses, the inability to successfully obtain further funding, the inability to raise capital on terms acceptable to the company, the inability to compete effectively in the marketplace, the inability to complete the proposed acquisition and such other risks that could cause the actual results to differ materially from those contained in the company’s projections or forward-looking statements. All forward looking statements in this press release are based on information available to the company as of the date hereof, and the company undertakes no obligation to update forward-looking statements to reflect events or circumstances occurring after the date of this press release.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Posted by AGORACOM-JC
at 7:16 AM on Wednesday, September 9th, 2020
Announced partnership with celebrity author, podcast host and parenting expert, Hilaria Baldwin
Baldwin has joined Else Nutrition as part of its U.S. launch marketing efforts around its Complete Toddler Nutrition
VANCOUVER, BC / September 9, 2020 / Else Nutrition Holdings(TSXV:BABY)(OTCQX:BABYF)(FSE:0YL)(“Else” or the “Company”), is pleased to announce its partnership with celebrity author, podcast host and parenting expert, Hilaria Baldwin. Baldwin has joined Else Nutrition as part of its U.S. launch marketing efforts around its Complete Toddler Nutrition.
As a mom who has always advocated a plant-based lifestyle, the collaboration originated from Hilaria’s own search for a suitable toddler formula alternative for her children. Baldwin will help Else through creative social media and video content that highlights her findings and journey as a plant-based mother.
“Hilaria embodies our brand values through her desire to take baby nutrition to the next level with a heightened awareness for health and wellness,” said Mrs. Hamutal Yitzhak, CEO and Co-Founder of Else. “She is a true champion of the cause, which makes us beyond excited about this collaboration. Together, we hope to raise awareness of the benefits of clean-label, plant-based baby nutrition for this generation and the future ones to come.”
“I am thrilled to be partnering with Else Nutrition. As many of you know, my family primarily eats a dairy-free, plant-based diet. I nurse my babies and am always looking for a plant-based toddler formula to transition to once they are weaned. There hasn’t been anything suitable except soy until now. Else is complete, whole Nutrition and my toddler Romeo genuinely loves it. It’s really the alternative that I had been looking for, and I believe that so many other parents like myself have been longing for it as well,” said Mrs. Hilaria Baldwin.
Most recently, Else made its debut on national U.S. television. Baldwin appeared on E!’s popular midday show, Daily Pop, where she explained why Else is her choice for her toddler, Romeo. Else Nutrition’s Plant-Based Complete Nutrition for Toddlers & Babies (12+ mo.) is available for order on Else’s e-store at elsenutrition.com.
About Else Nutrition Holdings Inc.
Else Nutrition GH Ltd. is an Israel-based food and nutrition company focused on developing innovative, clean and plant-based food and nutrition products for infants, toddlers, children, and adults. Its revolutionary, plant-based, non-soy, formula is a clean-ingredient alternative to dairy-based formula. Else Nutrition (formerly INDI) won the “2017 Best Health and Diet Solutions” award at the Global Food Innovation Summit in Milan. The holding company, Else Nutrition Holdings Inc, is a publicly traded company, listed as TSX Venture Exchange under the trading symbol BABY and is quoted on the US OTC Markets QB board under the trading symbol BABYF and on the Frankfurt Exchange under the symbol 0YL. Else’s Executives includes leaders hailing from leading infant nutrition companies. Many of Else advisory board members had past executive roles in companies such as Mead Johnson, Abbott Nutrition, Plum Organics and leading infant nutrition Societies, and some of them currently serve in different roles in leading medical centers and academic institutes such as Boston Children’s Hospital, Pediatrics at Harvard Medical School, USA, Tel Aviv University, Schneider Children’s Medical Center of Israel, Rambam Medical Center and Technion, Israel and University Hospital Brussels, Belgium.
About Hilaria Baldwin
Hilaria Baldwin (@hilariabaldwin) is the Co-Host of Mom Brain, Apple’s #1 parenting podcast; the author of The Living Clearly Method: 5 Principles for a Fit Body, Healthy Mind & Joyful Life (Rodale; December 2016); and Co-Founder of Yoga Vida in NYC. She is also a monthly contributor to TODAY.com’s One Small Thing platform and to People’s People Parents Squad. Hilaria lives in NYC with her husband Alec and their four children, Carmen Gabriella, Rafael Thomas, Leonardo Angel and Romeo Alejandro David, and they’re currently expecting their fifth child.
For more information, visit: elsenutrition.com or @elsenutrition on Facebook and Instagram.
For additional information, contact:
Ms. Hamutal Yitzhak, CEO, Co-Founder & Director ELSE Nutrition Holdings Inc. E: [email protected] P: +972(0)3-6445095
Mr. Sokhie Puar, Director ELSE Nutrition Holdings Inc. E: [email protected] P: 604-603-7787
TSX Venture Exchange
Neither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Caution Regarding Forward-Looking Statements
This press release contains statements that may constitute “forward-looking statements” within the meaning of applicable securities legislation. Forward-looking statements are typically identified by words such as “will” or similar expressions. Forward-looking statements in this press release include statements with respect to the Company’s anticipated partnership with Mrs. Baldwin. Such forward-looking statements reflect current estimates, beliefs and assumptions, which are based on management’s perception of current conditions and expected future developments, as well as other factors management believes are appropriate in the circumstances. No assurance can be given that the foregoing will prove to be correct. Forward-looking statements made in this press release assume, among others Forward-looking statements made in this press release assume, among others, the successful partnership between the Company and Mrs. Baldwin. Actual results may differ from the estimates, beliefs and assumptions expressed or implied in the forward-looking statements. Readers are cautioned not to place undue reliance on any forward-looking statements, which reflect management’s expectations only as of the date of this press release. The Company disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
/cdn.vox-cdn.com/uploads/chorus_image/image/67378681/acastro_200901_1777_twitch_0003.0.0.jpg)
